Discover the World’s Fastest Business Insights
Get real-time alerts on funding rounds, executive hires, acquisitions, and more— plus verified contact details and AI-powered outreach to connect faster.
Sign up now to unlock exclusive data and opportunities.
Repertoire Immune Medicines Receives Funding From COVID-19 High Performance Computing Consortium
Company Info
Company news
Mon, 29 Apr 2024 07:00:00 GMT
Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases - PR Newswire
Mon, 29 Apr 2024 07:00:00 GMT
Repertoire pivot pays dividends with Bristol Myers deal - BioPharma Dive
Mon, 29 Apr 2024 07:00:00 GMT
Bristol Myers pays $65M to expand Repertoire of autoimmune assets - Fierce Biotech
Mon, 29 Apr 2024 07:00:00 GMT
BMS, Repertoire Ink Potential $1.8B Deal to Find Vaccines for Autoimmune Diseases - BioSpace
Mon, 29 Apr 2024 07:00:00 GMT
Bristol Myers buys into Repertoire's autoimmune vaccines, giving new life to Flagship startup - Endpoints News
Tue, 30 Apr 2024 07:00:00 GMT
Tolerizing vaccines for autoimmune diseases tempt BMS into $1.8bn collaboration - BioPharma-Reporter.com
Wed, 01 May 2024 07:00:00 GMT
Bristol Myers Squibb and Repertoire enter autoimmune disease partnership worth over $1.8bn - PMLiVE
Mon, 29 Apr 2024 07:00:00 GMT
After 'reset,' Flagship startup lands $1.8B Bristol Myers Squibb deal - The Business Journals
Mon, 07 Nov 2022 08:00:00 GMT
Torben Straight Nissen Joins Repertoire® Immune Medicines as Chief Executive Officer - Business Wire
Fri, 10 Feb 2023 08:00:00 GMT
Did irregular shifts in clinical trial progression at Flagship’s Repertoire foreshadow the termination of its immuno-oncology program? - STAT
Never Miss an Opportunity: Your #1 Sales Intelligence Tool
Get lightning-fast updates on funding rounds, executive hires, contract awards, and more—powered by AI-driven insights to help you connect with the right prospects first.
Related people
FH